Botanix Pharmaceuticals Limited

For the first half of fiscal 2026, Botanix reported total revenue of $16.5 million, including royalty revenue, versus $346,000 in the prior corresponding period. Materials and related expenses were $6 million, direct operating expenses were $36.6 million, adjusted EBITDA loss was $26.1 million, and cash and equivalents ended at $31.6 million. Sofdra revenue was $16.2 million in the half, with total prescriptions shipped of 45,800, up 171% from 16,800 in the second half of fiscal 2025. Net revenue rose from $5.1 million to $16.2 million, a 219% increase. Management did not provide quarterly guidance, but said revenue is expected to keep growing, gross-to-net should improve toward 30% to 40%, and an alternate API supplier could reduce cost of goods sold by 25% to 40%.

CEO Howie McKibbon framed the quarter as early proof that Sofdra and the commercial platform are working above expectations. He emphasized the product’s large addressable market, patent life to 2040, and the company’s ability to scale without needing to add much incremental infrastructure. His tone was optimistic and strategic, with repeated focus on using the platform to add future products, expand licensing, and improve margins through supply-chain changes.

CFO Chris Lesovitz highlighted a scaling commercial business with higher spend tied to launch investment. He cited $16.5 million in total revenue, $6 million of materials and related expenses, $36.6 million of direct operating expenses, a $26.1 million adjusted EBITDA loss, and $31.6 million in cash and equivalents. He also broke out sales and marketing at $24.7 million, employee costs at $7 million, and G&A at $3.2 million, noting that the cost base should eventually lag revenue as adoption grows.

Most of the Q&A centered on API supply and the $45 million capital raise. Management explained that Sofdra’s API is not off-the-shelf because it is a new chemical entity, so an alternate supplier must be developed, validated, and inspected; they said this takes time but could cut COGS by 25% to 40% and add redundancy. They clarified the current API contract requires purchases in March and April 2026 and January 2027, then one purchase per year in 2028 through 2030, and said they are trying to spread near-term payments to preserve working capital. They also explained the raise proceeds will fund API and manufacturing purchases, alternate supplier setup, marketing, operating expenses, and working capital.